Aim and background: Growth hormone (GH) treatment of short children born SGA and its effects on growth varies greatly between treated individuals. In the present study we tested the performance of a preexisting growth prediction model (Ranke et al.; JCE&M 2003 pp. 125131) to estimate 1st-year height velocity (HV) in a german subcohort of prepubertal children born SGA treated with GH (Omnitrope).
Methods: 190 treatment-naïve prepubertal children born SGA (72 girls) were enrolled within the international post authorisation safety study PATRO children. The model was validated by comparing predicted and observed HV in the first year of treatment with Omnitrope.
Results: Baseline characteristics at start of GH treatment and predicted vs. observed 1-year growth rate as well as the index of responsiveness are given in the table. Mean predicted and observed 1-year HV were similar and the mean index of responsiveness was close to zero.
|Age at GH start||6.58||2.14||6.00|
|Height SDS baseline||−3.11||0.79||−2.95|
|GH dose at start (mg/kg/day)||0.032||0.006||0.033|
|1st-year Δ-height SDS||0.731||0.30||0.74|
|1st-year observed HV (cm/yr)||8.58||1.54||8.80|
|1st-year predicted HV (cm/yr)||8.61||0.73||8.78|
|Index of Responsiveness (IoR)||−0.024||1.089||−0.020|
Conclusions: Our results indicate accurate performance of the growth prediction model. It may therefore be used for growth monitoring and individualization of GH therapy in children treated with the biosimilar Omnitrope.
27 - 29 Sep 2018
European Society for Paediatric Endocrinology